INTRODUCTION
Chromaffin cells in the adrenal medulla produce and release several neuroaetive substances which make them viable candidates as a graft source for pain alleviation. In particular, these cells synthesize and release opioid peptide products from the proenkephalin precursor /2,12,13,23,30/, in addition to catecholamines. Notably, both opioid and adrenergic agonists reduce nociception when injected locally into the spinal subarachnoid space. Furthermore, the co-administration of subeffective doses of both types of agents appears to synergistically produce potent analgesia, with limited tolerance development /4,22,29,36 /. Thus, adrenal medullary transplants may provide an ideal combination of pain-reducing neuroactive agents for the long-term alleviation of pain. Previous studies in our laboratory have demonstrated that the transplantation of adrenal medullary tissue into the spinal subaraehnoid space of rats can reduce pain symptoms in acute and chronic pain models /10,18,20 /. This is most likely due to the co-release of both opioid peptides and catecholamines from the transplanted cells since it can be blocked by either opioid or (x-adrenergic antagonists /18,20/. Furthermore, adrenal medullary transplants result in elevated CSF levels of Met-enkephalin and cateeholamines for at least 6 months following transplantation/15,16/. The success of these studies has led to limited clinical trials in cancer pain patients with promising findings/19/.
Prior to attempting larger-scale clinical trials, several basic issues need to be resolved. Many of these can be addressed, at least initially, in the laboratory. For example, the preparation of adrenal medullary allogratt tissue for transplantation in order to optimize pain-reducing capabilities, as well as logistics, is critical to the success of this approach. Previous studies in our laboratory have utilized adrenal medullary tissue from two donor glands. This reliably reduces pain sensitivity and increases CSF levels of pain-reducing neuroactive substances following transplantation into the host spinal subarachnoid space. However, neither the minimum nor optimum amount of donor tissue for pain reduction has been determined. In addition, in previous studies, adrenal medullary tissue has been removed from donors and transplanted immediately into the spinal subarachnoid space of host animals. This procedure may be inconvenient for clinical purposes, since it is otten difficult to coordinate harvesting of donor tissue with timing for surgical implantation. One approach to overcoming this difficulty would be to maintain the donor tissue in culture prior to transplantation. Another advantage of maintaining tissue in explant culture is that it may allow for recovery from anoxic trauma following dissection. Thus, the goal of the present studies was to assess optimal procedures to increase the likelihood of successful pain reduction by adrenal medullary allogratts. A preliminary account of these results has been presented previously/27/.
MATERIALS AND METHODS

Animals
In all of the following studies, male SpragueDawley rats (250-300 g) were used as both hosts and donors. The rats were obtained from Sasco Laboratories (WI) Similarly basal DA levels were slightly, but significantly, increased in animals receiving [2] [3] [4] [5] [6] [7] [8] [9] [10] adrenal medullae (P < 0.05). Fig. 3B shows catecholamine levels in spinal CSF samples following systemic nicotine injection. Nicotine injection had no effect on the CSF levels of NE, EPI, or DA in control transplanted animals (P > 0.05 compared to basal levels). In contrast, NE and EPI levels were increased by nicotine in all animals with adrenal medullary transplants. In particular, NE levels were consistently increased four-or fivefold in animals with 2-10 transplanted adrenal medullae.
Nicotine-stimulated DA was also apparent, but only in animals with larger amounts Of adrenal medullary tissue transplanted (8-10 glands).
Stimulated release of NE in adrenal medullary transplanted animals was increased in animals receiving four compared to two adrenal medullae (P < 0.05), but further increases were not apparent (P > 0.05).
Met-enkephalin release in spinal superfusates is shown in Fig. 3C . Mean basal levels of Metenkephalin release were higher in animals with transplants of 4 to 10 adrenal medullae than those of control animals or with transplants of one to two adrenal medullae (P < 0.05). Nicotine produced significant increases in Met-enkephalin release from basal levels in animals with transplants of two to ten adrenal medullae (P < 0.01), but not in animals with transplants of either one adrenal medulla or control muscle (P > 0.05). An intermediate amount of adrenal medullary tissue (6 medullae) appeared to release the highest levels of Met-enkephalin following nicotine, with decrements when more tissue was added, but the differences between 2 and 10 adrenal medullae were not statistically significant (P > 0.05).
The appearance of host spinal cord from an animal receiving 10 adrenal medullae is shown in Figure 4 . Fig. 4A is a low magnification showing Effects of explanted adrenal medullary tissue in the spinal cord subaraclmoid space of rats on pain sensitivity assessed by the paw pinch test. The abscissa shows the number of days explants were maintained in culture prior to transplantation. The ordinate is the threshold for response to the noxious stimulus as determined by the test. various time periods ranging from 1-30 days (P < 0.05). Similar to earlier findings, this dose of nicotine produced no effect in animals with control striated muscle transplants (P > 0.05, not shown).
The antinoeiceptive potency of the explants was maintained without significant decrement from 2 to 4, 8, and 12 weeks post-transplantation (Fig. 5 A-D; P > 0.05 between times after transplantation). The results following maintenance in explant culture revealed that there was no reduction in the potency of adrenal medullary transplants whether they were implanted immediately following dissection or kept VOLUME 5, NO. 1, 1994 in tissue culture for up to 30 days prior to transplantation (P > 0.05 between transplant groups at all time points). Findings using the paw pinch test were virtually identical, showing no significant decrements in antinoeiceptive potency of the transplants over time, whether the medullary tissue was transplanted immediately, or after 1-30 days in culture (Fig. 6 A-D) .
Following termination of behavioral testing, animals receiving adrenal medullary transplants or explants were perfused, and their spinal cords processed for tyrosine hydroxylase (TH) immunocytochemistry to assess chromaffin cell viability (Fig. 7) 
